NP_891555.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
152,757 Da
NCBI Official Full Name
vascular endothelial growth factor receptor 3 isoform 1
NCBI Official Synonym Full Names
fms-related tyrosine kinase 4
NCBI Protein Information
vascular endothelial growth factor receptor 3; FLT-4; VEGFR-3; soluble VEGFR3 variant 1; soluble VEGFR3 variant 2; soluble VEGFR3 variant 3; fms-like tyrosine kinase 4; tyrosine-protein kinase receptor FLT4
UniProt Protein Name
Vascular endothelial growth factor receptor 3
UniProt Synonym Protein Names
Fms-like tyrosine kinase 4; FLT-4; Tyrosine-protein kinase receptor FLT4
UniProt Synonym Gene Names
UniProt Entry Name
VGFR3_HUMAN
NCBI Summary for VEGFR 3
This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA. [provided by RefSeq, Jul 2008]
UniProt Comments for VEGFR 3
VEGFR3: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3- kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr- 185', and of AKT1 at 'Ser-473'. Interacts with VEGFC and VEGFD. Monomer in the absence of bound VEGFC or VEGFD. Homodimer in the presence of bound VEGFC or VEGFD. Can also form a heterodimer with KDR. Interacts with PTPN14; the interaction is enhanced by stimulation with VEGFC. Interacts with CRK, GRB2, PTK2/FAK1, SHC1, PIK3R1 and PTPN11/SHP- 2. Identified in a complex with SRC and ITGB1. Detected in endothelial cells. Widely expressed. Detected in fetal spleen, lung and brain. Detected in adult liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney. Present in an inactive conformation in the absence of bound ligand. Binding of VEGFC or VEGFD leads to dimerization and activation by autophosphorylation on tyrosine residues. Inhibited by MAZ51. Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Protein kinase, TK; Protein kinase, tyrosine (receptor); EC 2.7.10.1; Kinase, protein; Membrane protein, integral; TK group; VEGFR family
Chromosomal Location of Human Ortholog: 5q35.3
Cellular Component: integral to plasma membrane; cytoplasm; extracellular region; plasma membrane; nucleus; receptor complex
Molecular Function: vascular endothelial growth factor receptor activity; protein binding; growth factor binding; transmembrane receptor protein tyrosine kinase activity; protein phosphatase binding; ATP binding
Biological Process: peptidyl-tyrosine phosphorylation; protein amino acid autophosphorylation; positive regulation of JNK cascade; positive regulation of MAPKKK cascade; vasculature development; lymphangiogenesis; positive regulation of cell proliferation; blood vessel morphogenesis; positive regulation of endothelial cell proliferation; sprouting angiogenesis; positive regulation of protein amino acid phosphorylation; vascular endothelial growth factor receptor signaling pathway; lymph vessel development; transmembrane receptor protein tyrosine kinase signaling pathway; negative regulation of apoptosis
Disease: Hemangioma, Capillary Infantile; Lymphedema, Hereditary, Ia
Research Articles on VEGFR 3
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with VEGFR 3 elisa kit
Pathways associated with VEGFR 3 elisa kit
Diseases associated with VEGFR 3 elisa kit
Disease Name |
Pubmed Publications |
Neoplasms Antibodies |
>39 publications with VEGFR 3 and Neoplasms |
Lymphatic Diseases Antibodies |
>25 publications with VEGFR 3 and Lymphatic Diseases |
LYMPHEDEMA, HEREDITARY, IA Antibodies |
>24 publications with VEGFR 3 and LYMPHEDEMA, HEREDITARY, IA |
Carcinoma Antibodies |
>13 publications with VEGFR 3 and Carcinoma |
Edema Antibodies |
>9 publications with VEGFR 3 and Edema |
Neoplasms, Experimental Antibodies |
>6 publications with VEGFR 3 and Neoplasms, Experimental |
Adenocarcinoma Antibodies |
>5 publications with VEGFR 3 and Adenocarcinoma |
Inflammation Antibodies |
>4 publications with VEGFR 3 and Inflammation |
Leukemia, Myeloid, Acute Antibodies |
>4 publications with VEGFR 3 and Leukemia, Myeloid, Acute |
Kidney Diseases Antibodies |
>3 publications with VEGFR 3 and Kidney Diseases |
Organs/Tissues associated with VEGFR 3 elisa kit
|